A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.